Two new drugs for moderate to severe psoriasis with high cholesterol
Part of Heart & circulation, Hormones & metabolism, Skin clinical trials.
This study tests two new medications given together—one that calms the immune system to treat psoriasis and another that lowers cholesterol. If you have both moderate-to-severe plaque psoriasis and high cholesterol, this combination may help clear your skin and improve your heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with plaque psoriasis (the most common type, with thick, scaly patches).
- Your psoriasis is moderate to severe, covering at least 10% of your body surface area.
- You have abnormal cholesterol levels (dyslipidemia), but not extremely high triglycerides or very high cardiovascular risk.
- You have not taken certain psoriasis treatments or cholesterol-lowering medications recently (within 2–12 weeks depending on the drug).
- You are not pregnant, breastfeeding, or planning pregnancy during the study, and you agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.